Mary Caffrey

The presenter of the study said the results show that children who are in a severe mass trauma need to be closely followed, and clinicians need to screen for trauma as a medical issue.

A discussion with University of California at Berkeley sociologist Arlie Hochschild, PhD, author of the best-seller Strangers in Their Own Land: Anger and Mourning on the American Right, addressed how social psychiatry can help bridge the current political divide.

The 175th Annual Meeting of the American Psychiatric Association, meeting in San Francisco, California, featured research about loneliness among minority women at midlife.

Some people living with type 1 diabetes are unhappy with commercial technology currently avaiable, while others see their choices limited by payer coverage decisions.

Dual inhibitors target both the SGLT1 and SGLT2 proteins in the digestive and renal systems to prevent reuptake of excess glucose.

Cure rates for Hodgkin lymphoma are high, but survivors may live for decades with side effects from chemotherapy. Finding a new treatment target could lead to fewer toxic effects.

Researchers say by targeting a protein that assists KRAS mutations, they have overcome the challeges of resistance to treatment in a mouse model.

As pharmaceutical manufacturers and pharmacy benefit managers point fingers over who is responsible for high drug prices, employers have the opportunity to demand change to business as usual, consultant Chris Robbins of Arxcel says.

Bryan Chiang's concept lets a user take a photo of the eye using a special adapter on the smartphone; the image is then analyzed to predict blood glucose levels.

Proof-of-concept studies suggest the treatment that targets CD47 produces a strong response in patients with diffuse large B-cell lymphoma (DLBCL) with fewer adverse effects than current options.

The use of the circulating tumor DNA workflow demonstrated a proof of concept for this system of guiding treatment in the most common form of ovarian cancer.

Older patients who are improperly diagnosed may not gain access to insulin and delivery and monitoring tools, such as pumps or continuous glucose monitoring.

Radiotherapy after chemotherapy is controversial, as evidenced by the fact that doctors for some patients in the study did not follow the protocol for those assigned to radiotherapy and may have affected the results.

The results may lead to the first new option in years for youth with type 2 diabetes, besides metformin and insulin.

The CDC created the National Diabetes Prevention Program following a study of a lifestyle intervention; new results show that more than a third of adults who are referred to a program take part, but only a fraction are referred.

Modifications to the engineering of the chimeric antigen receptor (CAR) mean that the patient produces fewer cytokines and has time to clear them before they build up in the bloodstream.

The study by researchers at Penn State College of Medicine found those with type 1 diabetes who read blogs had lower glycated hemoglobin (A1C) levels, and the combination of reading blogs and using continuous glucose monitoring produced the best glycemic control.

The Bold Goal Program began with the mission of improving health in target communities by 20% by 2020.

Managed care updates.

Regulatory and clinical updates.

Conference coverage updates from the Community Oncology Alliance's annual meeting.

Updates from the Association of Community Cancer Centers annual meeting.

Policy updates from the National Comprehensive Cancer Network's annual meeting.

The scientists used machine learning to test the algorithm and believe it could double the number of women who would be treated with poly (ADP-ribose) polymerase (PARP) inhibitors for breast cancer.

Clinical updates from the National Comprehensive Cancer Network's annual meeting.

Academic medical centers and a group representing community oncology practices have both raised concerns about CMS’ proposed reimbursement plan for chimeric antigen receptor (CAR) T-cell therapy, the individually manufactured gene treatments that are revolutionizing cancer care. The plan will be finalized next month, a year after the federal government launched a national coverage analysis to determine how to pay for these lifesaving yet expensive cancer treatments.

Results of the landmark study, the first in a series of renal outcomes studies for SGLT2 inhibitors, will be of great interest to policy makers given the cost of dialysis to Medicare.

A preliminary study discussed how a vaccine regimen stimulated dendritic cells to attack tumors, which could point to a new way of making immunotherapy effective in cancers that have proved resistant to treatment thus far.

The filing comes as recent upgrades to NCCN guidelines expand the role of testing in the treatment of ovarian cancer.

The program comes as Congress has singled out the cost of insulin in its scrutiny of drug prices. Patients with type 1 diabetes cannot survive without the hormone, and press reports have highlighted the plight of young adults who ration insulin after they reach age 26 and cannot stay on family insurance plans.